MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...

Merck (NYSE:MRK) recently initiated the IDeate-Prostate01 phase 3 trial, dosing the first patient for its investigational drug ifinatamab deruxtecan, aimed at treating metastatic castration-resistant ...

Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...